Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.275    0.025 (2.04%)
Bid:
1.20
Ask:
1.35
Spread: 0.15 (12.50%)
Market Cap: £20.07m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Additional Listing

8 Apr 2014 18:21

RNS Number : 3774E
Epistem Holdings plc
08 April 2014
 



 

 

Epistem Holdings Plc

Additional Listing

Epistem (AIM: EHP) announces that 5,000 new ordinary shares of 1.5 pence each (the "New Ordinary Shares") have been issued and allotted pursuant to the exercise of options under the Epistem Holdings Plc EMI Share Option Scheme.

Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 14th April, 2014 and, when issued, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.

Following the admission to trading of the New Ordinary Shares, Epistem will have 9,753,240 ordinary shares of 1.5 pence each in issue.

 

 

For further details please contact:

 

Epistem Plc

Matthew Walls, CEO +44 161 606 7258

John Rylands, Finance Director +44 161 606 7244

 

Peel Hunt LLP

James Steel +44 20 7418 8900

Clare Terlouw

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
LISUGUUPCUPCGMR
Date   Source Headline
25th Jan 202111:00 amRNSPrice Monitoring Extension
18th Jan 202112:29 pmRNSHolding(s) in Company
18th Jan 20217:00 amRNSNotice of Results
30th Dec 202012:50 pmRNSResult of AGM
23rd Dec 202011:39 amRNSHolding(s) in Company
21st Dec 20202:48 pmRNSResponse to new COVID strain
17th Dec 20209:12 amRNSHolding(s) in Company
16th Dec 20209:05 amRNSSecond Price Monitoring Extn
16th Dec 20209:00 amRNSPrice Monitoring Extension
16th Dec 20207:00 amRNSNotification of intent to distribute in the USA
11th Dec 20207:00 amRNSConversion of Remaining Loan Notes
7th Dec 20207:00 amRNSAdditional Listing
3rd Dec 20207:00 amRNSAIHL hospital study completion
30th Nov 20207:00 amRNSBlock listing Interim Review
26th Nov 20204:41 pmRNSSecond Price Monitoring Extn
26th Nov 20204:35 pmRNSPrice Monitoring Extension
20th Nov 20207:00 amRNSHigh clinical accuracy in India study
17th Nov 20207:00 amRNSFinal Results
10th Nov 202011:05 amRNSSecond Price Monitoring Extn
10th Nov 202011:00 amRNSPrice Monitoring Extension
2nd Nov 20204:40 pmRNSSecond Price Monitoring Extn
2nd Nov 20204:35 pmRNSPrice Monitoring Extension
29th Oct 20207:00 amRNSNotice of Results
28th Oct 20204:41 pmRNSSecond Price Monitoring Extn
28th Oct 20204:36 pmRNSPrice Monitoring Extension
22nd Oct 20207:00 amRNSPoint-of-Care solution to detect SARS-CoV-2 virus
19th Oct 202012:44 pmRNSHolding(s) in Company
12th Oct 202011:18 amRNSHolding(s) in Company
9th Oct 20207:00 amRNSHolding(s) in Company
6th Oct 20207:00 amRNSHolding(s) in Company
1st Oct 20206:09 pmRNSHolding(s) in Company
30th Sep 20207:00 amRNSSouth African approval
28th Sep 20207:00 amRNSPartial Conversion of Loan Notes
25th Sep 20207:00 amRNSVerification with Beckman Coulter Life Sciences
21st Sep 20209:40 amRNSHolding(s) in Company
18th Sep 20202:06 pmRNSSecond Price Monitoring Extn
18th Sep 20202:01 pmRNSPrice Monitoring Extension
17th Sep 20209:27 amRNSHolding(s) in Company
16th Sep 20203:15 pmRNSHolding(s) in Company
16th Sep 20209:00 amRNSHolding(s) in Company
15th Sep 20201:12 pmRNSHolding(s) in Company
14th Sep 20204:40 pmRNSSecond Price Monitoring Extn
14th Sep 20204:35 pmRNSPrice Monitoring Extension
14th Sep 20207:00 amRNSHolding(s) in Company
4th Aug 20202:05 pmRNSSecond Price Monitoring Extn
4th Aug 20202:00 pmRNSPrice Monitoring Extension
4th Aug 20207:00 amRNSCollaboration to automate COVID-19 PCR testing
23rd Jul 202011:06 amRNSSecond Price Monitoring Extn
23rd Jul 202011:00 amRNSPrice Monitoring Extension
22nd Jul 20203:13 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.